Literature DB >> 19420244

Axonal stress kinase activation and tau misbehavior induced by kinesin-1 transport defects.

Tomás L Falzone1, Gorazd B Stokin, Concepción Lillo, Elizabeth M Rodrigues, Eileen L Westerman, David S Williams, Lawrence S B Goldstein.   

Abstract

Many neurodegenerative diseases exhibit axonal pathology, transport defects, and aberrant phosphorylation and aggregation of the microtubule binding protein tau. While mutant tau protein in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP17) causes aberrant microtubule binding and assembly of tau into filaments, the pathways leading to tau-mediated neurotoxicity in Alzheimer's disease and other neurodegenerative disorders in which tau protein is not genetically modified remain unknown. To test the hypothesis that axonal transport defects alone can cause pathological abnormalities in tau protein and neurodegeneration in the absence of mutant tau or amyloid beta deposits, we induced transport defects by deletion of the kinesin light chain 1 (KLC1) subunit of the anterograde motor kinesin-1. We found that upon aging, early selective axonal transport defects in mice lacking the KLC1 protein (KLC1-/-) led to axonopathies with cytoskeletal disorganization and abnormal cargo accumulation. In addition, increased c-jun N-terminal stress kinase activation colocalized with aberrant tau in dystrophic axons. Surprisingly, swollen dystrophic axons exhibited abnormal tau hyperphosphorylation and accumulation. Thus, directly interfering with axonal transport is sufficient to activate stress kinase pathways initiating a biochemical cascade that drives normal tau protein into a pathological state found in a variety of neurodegenerative disorders including Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19420244      PMCID: PMC3849468          DOI: 10.1523/JNEUROSCI.0780-09.2009

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  54 in total

1.  Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein.

Authors:  J Lewis; E McGowan; J Rockwood; H Melrose; P Nacharaju; M Van Slegtenhorst; K Gwinn-Hardy; M Paul Murphy; M Baker; X Yu; K Duff; J Hardy; A Corral; W L Lin; S H Yen; D W Dickson; P Davies; M Hutton
Journal:  Nat Genet       Date:  2000-08       Impact factor: 38.330

2.  Phosphorylation of microtubule-associated protein tau by isoforms of c-Jun N-terminal kinase (JNK).

Authors:  Hirotaka Yoshida; C James Hastie; Hilary McLauchlan; Philip Cohen; Michel Goedert
Journal:  J Neurochem       Date:  2004-07       Impact factor: 5.372

Review 3.  Axonal transport and Alzheimer's disease.

Authors:  Gorazd B Stokin; Lawrence S B Goldstein
Journal:  Annu Rev Biochem       Date:  2006       Impact factor: 23.643

4.  Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases.

Authors:  M Goedert; M Hasegawa; R Jakes; S Lawler; A Cuenda; P Cohen
Journal:  FEBS Lett       Date:  1997-06-02       Impact factor: 4.124

5.  Accelerated filament formation from tau protein with specific FTDP-17 missense mutations.

Authors:  P Nacharaju; J Lewis; C Easson; S Yen; J Hackett; M Hutton; S H Yen
Journal:  FEBS Lett       Date:  1999-03-26       Impact factor: 4.124

6.  Formation of phospho-SAPK/JNK granules in the hippocampus is an early event in Alzheimer disease.

Authors:  Sarita Lagalwar; Angela L Guillozet-Bongaarts; Robert W Berry; Lester I Binder
Journal:  J Neuropathol Exp Neurol       Date:  2006-05       Impact factor: 3.685

Review 7.  A decade of modeling Alzheimer's disease in transgenic mice.

Authors:  Eileen McGowan; Jason Eriksen; Michael Hutton
Journal:  Trends Genet       Date:  2006-03-29       Impact factor: 11.639

8.  Tau protein hyperphosphorylation in sporadic ALS with cognitive impairment.

Authors:  M J Strong; W Yang; W L Strong; C Leystra-Lantz; H Jaffe; H C Pant
Journal:  Neurology       Date:  2006-06-13       Impact factor: 9.910

9.  Mutation in the tau gene in familial multiple system tauopathy with presenile dementia.

Authors:  M G Spillantini; J R Murrell; M Goedert; M R Farlow; A Klug; B Ghetti
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

Review 10.  Role of axonal transport in neurodegenerative diseases.

Authors:  Kurt J De Vos; Andrew J Grierson; Steven Ackerley; Christopher C J Miller
Journal:  Annu Rev Neurosci       Date:  2008       Impact factor: 12.449

View more
  52 in total

1.  Loss of the m-AAA protease subunit AFG₃L₂ causes mitochondrial transport defects and tau hyperphosphorylation.

Authors:  Arun Kumar Kondadi; Shuaiyu Wang; Sara Montagner; Nikolay Kladt; Anne Korwitz; Paola Martinelli; David Herholz; Michael J Baker; Astrid C Schauss; Thomas Langer; Elena I Rugarli
Journal:  EMBO J       Date:  2014-03-28       Impact factor: 11.598

2.  JIP3 Activates Kinesin-1 Motility to Promote Axon Elongation.

Authors:  Dana Watt; Ram Dixit; Valeria Cavalli
Journal:  J Biol Chem       Date:  2015-05-05       Impact factor: 5.157

Review 3.  Altered microtubule dynamics in neurodegenerative disease: Therapeutic potential of microtubule-stabilizing drugs.

Authors:  Kurt R Brunden; Virginia M-Y Lee; Amos B Smith; John Q Trojanowski; Carlo Ballatore
Journal:  Neurobiol Dis       Date:  2016-12-22       Impact factor: 5.996

4.  KymoAnalyzer: a software tool for the quantitative analysis of intracellular transport in neurons.

Authors:  Sylvia Neumann; Romain Chassefeyre; George E Campbell; Sandra E Encalada
Journal:  Traffic       Date:  2016-12-11       Impact factor: 6.215

5.  The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice.

Authors:  Bin Zhang; Jenna Carroll; John Q Trojanowski; Yuemang Yao; Michiyo Iba; Justin S Potuzak; Anne-Marie L Hogan; Sharon X Xie; Carlo Ballatore; Amos B Smith; Virginia M-Y Lee; Kurt R Brunden
Journal:  J Neurosci       Date:  2012-03-14       Impact factor: 6.167

Review 6.  Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies.

Authors:  Kurt R Brunden; Carlo Ballatore; Virginia M-Y Lee; Amos B Smith; John Q Trojanowski
Journal:  Biochem Soc Trans       Date:  2012-08       Impact factor: 5.407

Review 7.  Microtubule-stabilizing agents as potential therapeutics for neurodegenerative disease.

Authors:  Kurt R Brunden; John Q Trojanowski; Amos B Smith; Virginia M-Y Lee; Carlo Ballatore
Journal:  Bioorg Med Chem       Date:  2013-12-30       Impact factor: 3.641

8.  Hippocampal to basal forebrain transport of Mn2+ is impaired by deletion of KLC1, a subunit of the conventional kinesin microtubule-based motor.

Authors:  Christopher S Medina; Octavian Biris; Tomas L Falzone; Xiaowei Zhang; Amber J Zimmerman; Elaine L Bearer
Journal:  Neuroimage       Date:  2016-10-14       Impact factor: 6.556

9.  Enhanced β-secretase processing alters APP axonal transport and leads to axonal defects.

Authors:  Elizabeth M Rodrigues; April M Weissmiller; Lawrence S B Goldstein
Journal:  Hum Mol Genet       Date:  2012-07-27       Impact factor: 6.150

10.  UV irradiation accelerates amyloid precursor protein (APP) processing and disrupts APP axonal transport.

Authors:  Angels Almenar-Queralt; Tomas L Falzone; Zhouxin Shen; Concepcion Lillo; Rhiannon L Killian; Angela S Arreola; Emily D Niederst; Kheng S Ng; Sonia N Kim; Steven P Briggs; David S Williams; Lawrence S B Goldstein
Journal:  J Neurosci       Date:  2014-02-26       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.